Fluoxetine elevates allopregnanolone in female rat brain but inhibits a steroid microsomal dehydrogenase rather than activating an aldo‐keto reductase
Open Access
- 24 November 2014
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 171 (24) , 5870-5880
Abstract
Background and Purpose: Fluoxetine, a selective serotonin reuptake inhibitor, elevates brain concentrations of the neuroactive progesterone metabolite allopregnanolone, an effect suggested to underlie its use in the treatment of premenstrual dysphoria. One report showed fluoxetine to activate the aldo‐keto reductase (AKR) component of 3α‐hydroxysteroid dehydrogenase (3α‐HSD), which catalyses production of allopregnanolone from 5α‐dihydroprogesterone. However, this action was not observed by others. The present study sought to clarify the site of action for fluoxetine in elevating brain allopregnanolone.Experimental Approach: Adult male rats and female rats in dioestrus were treated with fluoxetine and their brains assayed for allopregnanolone and its precursors, progesterone and 5α‐dihydroprogesterone. Subcellular fractions of rat brain were also used to investigate the actions of fluoxetine on 3α‐HSD activity in both the reductive direction, producing allopregnanolone from 5α‐dihydroprogesterone, and the reverse oxidative direction. Fluoxetine was also tested on these recombinant enzyme activities expressed in HEK cells.Key Results: Short‐term treatment with fluoxetine increased brain allopregnanolone concentrations in female, but not male, rats. Enzyme assays on native rat brain fractions and on activities expressed in HEK cells showed fluoxetine did not affect the AKR producing allopregnanolone from 5α‐dihydroprogesterone but did inhibit the microsomal dehydrogenase oxidizing allopregnanolone to 5α‐dihydroprogesterone.Conclusions and Implications: Fluoxetine elevated allopregnanolone in female rat brain by inhibiting its oxidation to 5α‐dihydroprogesterone by a microsomal dehydrogenase. This is a novel site of action for fluoxetine, with implications for the development of new agents and/or dosing regimens to raise brain allopregnanolone.Keywords
Funding Information
- Medical Research Council (GG0700379)
This publication has 59 references indexed in Scilit:
- RAPID RESPONSE TO FLUOXETINE IN WOMEN WITH PREMENSTRUAL DYSPHORIC DISORDERDepression and Anxiety, 2012
- Physiological insights into all-trans-retinoic acid biosynthesisBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2012
- Human hydroxysteroid dehydrogenases and pre-receptor regulation: Insights into inhibitor design and evaluationThe Journal of Steroid Biochemistry and Molecular Biology, 2011
- The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its DisordersEndocrine Reviews, 2011
- Neurosteroids and GABA-A Receptor FunctionFrontiers in Endocrinology, 2011
- Tolerance to allopregnanolone with focus on the GABA‐A receptorBritish Journal of Pharmacology, 2010
- Guidelines for reporting experiments involving animals: the ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- Animal research: Reporting in vivo experiments: The ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptakePsychopharmacology, 2006
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976